|
|
Vaccine Detail
|
Poly(HPMA)-MUC1(Tn)-TT P2-b-Poly(LMA) Conjugate Vaccine |
| Vaccine Information |
- Vaccine Name: Poly(HPMA)-MUC1(Tn)-TT P2-b-Poly(LMA) Conjugate Vaccine
- Target Pathogen: Cancer
- Target Disease: Cancer
- Type: Conjugate vaccine
- Status: Research
- Host Species for Licensed Use: Mouse
- Antigen: MUC1 (Nuhn et al., 2013)
- Immunization Route: Intramuscular injection (i.m.)
- Description: A polymer-based nanoparticle vaccine consisting of tumor-associated MUC1 tandem-repeat glycopeptide with Tn antigen conjugated with tetanus toxoid T-helper cell epitope P2 on a poly(N-(2-hydroxypropyl)methacrylamide)-block-poly(lauryl methacrylate) [P(HPMA)-b-P(LMA)] carrier. The block copolymer structure self-assembles into micellar nanoparticles (~86 nm). Vaccination with this conjugate induced MHC-II-mediated IgG antibody responses (IgG1, IgG2a, IgG2b, IgG3) in mice. All antisera (6/6) recognized MCF-7 breast tumor cells, with the block copolymer formulation showing strongest tumor cell binding. The MUC1 glycopeptide contains immunodominant motifs (PDTRP and GSTAP) with Tn antigen at threonine-18. The P2 epitope provides universal T-helper cell support (Nuhn et al., 2013).
|
| Host Response |
|
|
| References |
Nuhn et al., 2013: Nuhn L, Hartmann S, Palitzsch B, Gerlitzki B, Schmitt E, Zentel R, Kunz H. Water-soluble polymers coupled with glycopeptide antigens and T-cell epitopes as potential antitumor vaccines. Angewandte Chemie (International ed. in English). 2013; 52(40); 10652-10656. [PubMed: 24038824].
|
|
